Fundraising Fox
/Companies
Sign in

F-Prime Capital

also invests · investor profile

Boston, US · 8 known investors

Find your way into F-Prime Capital

Sign up to see every warm intro you have to F-Prime Capital

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the F-Prime Capital team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Beam Therapeutics develops CRISPR base editing technology to create precision genetic medicines for treating human diseases. The company focuses on therapeutic applications using single-letter DNA modifications.

BiotechDeep TechEnterprise SoftwareFoodTechMedical DevicesSaaS

Founders & leadership

JE
John EvansCEO

Investors · 8

Golden Sparrow Ventures, Llclisted by Golden Sparrow Ventures, Llc$400K – $1M
Arthur VenturesreportedMinneapolis · $1M – $10M

How we know: funding news · prnewswire.com · Not right? Tell us

Brevan Howard Digitalreported

How we know: funding news · Not right? Tell us

Kaiser Permanente VenturesreportedSan Francisco · $2M – $5M

How we know: funding news · prnewswire.com · Not right? Tell us

White Star CapitalreportedLondon · $500K – $7M

How we know: funding news · Not right? Tell us

Also in the syndicate · 2

Cognosante VenturesLionbird Venture Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Protenus Raises $11M From F-Prime Capital, Kaiser Permanente Venturesprnewswire.com · Jan 2018

Frequently asked questions

What does F-Prime Capital do?
Beam Therapeutics develops CRISPR base editing technology to create precision genetic medicines for treating human diseases. The company focuses on therapeutic applications using single-letter DNA modifications.
Who are F-Prime Capital's investors?
F-Prime Capital's investors include ASTUTIA Ventures GmbH, Golden Sparrow Ventures, Llc, Arthur Ventures, Brevan Howard Digital, Kaiser Permanente Ventures, White Star Capital.
Where is F-Prime Capital headquartered?
F-Prime Capital is headquartered in Boston, US.